Treatment of atopic dermatitis (AD) is evolving rapidly, yet many patients continue to cycle through topical therapies without achieving sustained disease control. Clinicians are increasingly asking a different question: when is it time to move beyond stepwise escalation and consider advanced therapy earlier in the treatment journey? 

Join dermatology experts for a case-based discussion exploring persistent care gaps in atopic dermatitis and how treatment strategies are shifting toward earlier intervention and long-term disease stability. 

The program will begin with a disease-state session examining real-world clinical scenarios, treatment decision points, and opportunities to improve outcomes. In the second half, faculty will present a therapeutic update discussing emerging clinical data and practical considerations for incorporating newer biologic therapies into AD management.

Product Theater Section 

Explore EBGLYSS® (lebrikizumab-lbkz) 

Join us for "Explore EBGLYSS® (lebrikizumab-lbkz)", an event where a clinician will discuss the efficacy and safety of EBGLYSS. This program features early and long-term data, safety, dosing information, and how to get patients started on EBGLYSS.

Topics will include: 

• Clinical trial efficacy data
• Long-term treatment outcomes
• Safety profile and dosing
• Practical considerations for getting patients started on EBGLYSS 

A brief Q&A session may follow, time permitting.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. 

Please see Prescribing Information and Patient Information at the product theater or at https://ebglyss.lilly.com/. 

Please see Instructions for Use included with the device. 

EBGLYSS® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.